Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.77 |
| ▸ | RAB9A | P51151 | 9/20 | 0.77 |
| ▸ | MEN1 | O00255 | 9/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.77 |
| ▸ | STAT3 | P40763 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | PKM | P14618 | 4/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.77 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.77 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375723 | 0.90 | MEN1 (0.71) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL27134627 | 0.89 | MEN1 (0.76) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL376119 | 0.87 | MEN1 (0.67) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Nitazoxanide SCHEMBL29373905 | 0.87 | STAT3 (1.00) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Nitazoxanide SCHEMBL40981 | 0.87 | STAT3 (1.00) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Nitazoxanide SCHEMBL5055353 | 0.87 | STAT3 (1.00) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL12994083 | 0.86 | NPC1 (0.79) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| SCHEMBL10253193 | 0.86 | MEN1 (0.66) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Nitazoxanide SCHEMBL28195534 | 0.86 | STAT3 (0.98) | NPC1RAB9AMEN1KMT2ASTAT3 | |
| Nitazoxanide SCHEMBL27651337 | 0.86 | STAT3 (0.98) | NPC1RAB9AMEN1KMT2ASTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171169-A1 | Combination chemotherapy for helminth infections | LAMINAR DIRECT CAPITAL, L.L.C. | 2005-08-04 | — | — | US | claimed |
| US-20230330069-A1 | USE OF THIAZOLIDES AGAINST CORONAVIRUSES | ROMARK LABORATORIES, L.C. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | ROMARK LABORATORIES, L.C. (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4199923-A1 | USE OF THIAZOLIDES AGAINST CORONAVIRUSES | Romark Laboratories, L.C. (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4182304-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | Romark Laboratories, L.C. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11426388-B2 | Controlled release pharmaceutical formulations of nitazoxanide | ROMARK LABORATORIES L.C. (US) | 2022-08-30 | — | — | US | disclosed |
| WO-2022046622-A1 | USE OF THIAZOLIDES AGAINST CORONAVIRUSES | ROMARK LABORATORIES L.C. (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022020243-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | ROMARK LABORATORIES L.C. (US) | 2022-01-27 | — | — | WO | disclosed |
| EP-3369427-B1 | SYNERGISTIC ANTIPARASITIC COMPOSITIONS AND SCREENING METHODS | TYRATECH INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10814612-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | ROMARK LABORATORIES L.C. (US) | 2020-10-27 | — | — | US | disclosed |
| US-7285567-B2 | Halogenated benzamide derivatives | ROMARK LABORATORIES, L.C. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1789040-A2 | HALOGENATED BENZAMIDE DERIVATIVES | Romark Laboratories, L.C. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060089396-A1 | Halogenated benzamide derivatives | U.S. BANK NATIONAL ASSOCIATION | 2006-04-27 | — | — | US | disclosed |
| WO-2006031566-A2 | HALOGENATED BENZAMIDE DERIVATIVES | ROMARK LABORATORIES, L.C. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20050171169-A1 | Combination chemotherapy for helminth infections | LAMINAR DIRECT CAPITAL, L.L.C. | 2005-08-04 | — | — | US | disclosed |
| EP-0755386-B1 | BENZAMIDE DERIVATIVE, COMPOSITIONS CONTAINING SAID DERIVATIVE AND USE THEREOF | ROMARK LAB LC (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6117894-A | MAINTAINS ITS STABILITY AFTER SIX MONTHS OR MORE OF STORAGE. | ROMARK LABORATORIES, L.C. (DE) | 2000-09-12 | — | — | US | disclosed |
| US-5968961-A | STORAGE STABILITY | ROMARK LABORATORIES, L.C. (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0755386-A1 | BENZAMIDE DERIVATIVE, COMPOSITIONS CONTAINING SAID DERIVATIVE AND USE THEREOF | Rossignol, Jean François (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1995028393-A1 | BENZAMIDE DERIVATIVE, COMPOSITIONS CONTAINING SAID DERIVATIVE AND USE THEREOF | ROSSIGNOL JEAN FRANCOIS (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10814612-B2 | Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections | MAVS, NFATC1, HAVCR2 | NPC1 148/4885RAB9A 340/4885MEN1 1307/4885 |
| US-11426388-B2 | Controlled release pharmaceutical formulations of nitazoxanide | NIT2, CYP3A7, NME2 | NPC1 191/4885RAB9A 635/4885MEN1 3679/4885 |
| US-20230303504-A1 | CRYSTALLINE SALTS OF TIZOXANIDE AND 2-HYDROXY-N-(5-CHLORO-1,3-THIAZOL-2-YL)BENZAMIDE (RM-4848) WITH ETHANOLAMINE, MORPHOLINE, PROPANOLAMINE, PIPERAZINE AND N-METHYLPIPERAZINE | SLC28A1, SLC28A2, NT5C | NPC1 401/4885RAB9A 2347/4885MEN1 1481/4885 |
| US-20060089396-A1 | Halogenated benzamide derivatives | CBR3, CBR1, HDAC3 | NPC1 673/4885RAB9A 678/4885MEN1 2995/4885 |
| US-20230330069-A1 | USE OF THIAZOLIDES AGAINST CORONAVIRUSES | ACE, TMPRSS4, ACE2 | NPC1 1228/4885RAB9A 1502/4885MEN1 4711/4885 |
| US-20050171169-A1 | Combination chemotherapy for helminth infections | NIT2, MLNR, EPX | NPC1 1887/4885RAB9A 2523/4885MEN1 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.